VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
PETS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
PETSPetMed Express, Inc.
$1.22$26M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksPETSBalance Sheet

PetMed Express, Inc. (PETS) Balance Sheet

27Y historyFree accessUpdated daily

The company's financial stability is under pressure, evidenced by a current ratio that has deteriorated to 0.84 as of 2026Q4.

Income StatementBalance SheetCash FlowRatios

PETS Balance Sheet

Annual statement

PETS Balance Sheet

PetMed Express, Inc. (PETS) balance sheet — 27-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMMar'26Mar'25Mar'24Mar'23Mar'22Mar'21Mar'20Mar'19Mar'18Mar'17Mar'16Mar'15Mar'14Mar'13Mar'12Mar'11Mar'10Mar'09Mar'08Mar'07Mar'06Mar'05Mar'04Mar'03Mar'02Mar'01Mar'00
Total Current Assets27.61M43.56M78.87M93.65M130.43M151M161.19M129.02M126.43M105.23M81.78M67.63M80.4M74.21M70.19M87.61M89.6M86.5M61.63M45.22M57.97M39.95M25.87M15.82M6.38M3.48M1.22M2.9M
Cash & Short-Term Investments13.08M21.41M54.72M55.3M104.09M111.08M118.72M103.76M100.53M77.94M58.73M37.64M51.2M33.84M33.65M57.15M59.78M53.14M30.13M25.05M39.44M23.22M12.68M3.28M984.17K737.28K408.7K311.85K
Cash Only13.08M21.41M54.72M55.3M104.09M111.08M118.72M103.76M100.53M77.94M58.73M37.64M35.61M18.3M18.16M46.8M49.66M53.14M30.13M20.27M316.47K23.22M12.68M3.28M984.17K737.28K408.7K311.85K
Short-Term Investments00000000000015.59M15.54M15.49M10.35M10.12M004.78M39.13M0000000
Accounts Receivable1.71M1.91M2.32M3.28M1.74M1.91M2.59M3.84M2.54M2.29M1.81M1.72M1.93M1.76M1.44M1.57M1.99M2.1M2.88M1.58M1.37M1.16M1.8M1.13M651.88K291.51K162.47K187.87K
Days Sales Outstanding3.863.893.734.372.482.553.114.943.273.062.652.683.072.752.312.413.133.214.793.053.083.076.054.44.333.325.934.67
Inventory8.47M13.61M16.2M28.56M19.02M32.45M34.42M17.88M21.37M23.34M20.23M25.59M25.07M35.73M31.6M26.22M25.14M29.06M26.78M17.91M16.09M15M11.18M11.18M4.27M2.31M631.39K1.75M
Days Inventory Outstanding34.7535.9437.4753.0737.3659.857.332.1841.4748.443.4758.9659.7583.7176.5360.5362.1372.4672.8957.2860.1165.7663.0773.149.4344.5636.1970.6
Other Current Assets4.26M6.64M5.63M6.33M4.72M681K4.5M3.53M1.41M882K1.02M2.44M2.2M1.12M3.5M2.47M2.04M1.25M1.48M00000000650.54K
Total Non-Current Assets36.16M37.63M69.83M76.24M39.57M25.32M26.31M26.3M28M29.6M31.02M22.65M2.45M4.17M2.99M3.46M16.68M17.67M20.34M28.23M3.25M2.67M2.25M2.66M2.64M1.17M3.28M3.42M
Property, Plant & Equipment25.61M26.84M29.82M28.09M26.18M24.46M25.45M25.45M27.14M28.74M30.16M20.93M1.57M1.31M2.13M2.6M3.43M4.43M5.06M1.9M1.99M1.5M1.29M1.69M1.5M1.12M3.19M3.31M
Fixed Asset Turnover6.16x6.67x7.61x9.76x9.80x11.18x11.93x11.17x10.44x9.53x8.26x11.21x146.20x178.16x106.86x91.74x67.48x53.80x43.38x98.95x81.51x91.87x84.24x55.67x36.72x28.59x3.14x4.44x
Goodwill0026.66M26.66M000000000000000000000000
Intangible Assets5.25M10.79M13.35M11.2M5.86M860K860K860K860K860K860K860K860K860K860K860K860K850K850K365K365K365K365K365K365K000
Long-Term Investments21.2M5.3M05.3M5M24.27M25.55M25.52M000-863K-840K-1.06M0012.39M12.39M14.43M25M00000000
Other Non-Current Assets0-5.3M04.99M-5M-25.32M-26.31M-26.3M-28M00863K840K2M-982K-1.23M-1M-1.25M-724.56K-260K014.17K14.17K21.82K200.16K50.16K94.23K116.91K
Total Assets63.76M81.19M148.7M169.88M170M176.32M187.5M155.32M154.43M134.84M112.81M90.28M82.85M78.38M73.18M91.06M106.29M104.17M81.96M73.45M61.22M42.62M28.12M18.48M9.03M4.65M4.5M6.33M
Asset Turnover2.03x2.20x1.53x1.61x1.51x1.55x1.62x1.83x1.84x2.03x2.21x2.60x2.77x2.98x3.11x2.62x2.18x2.29x2.68x2.56x2.65x3.23x3.85x5.09x6.09x6.88x2.22x2.32x
Asset Growth %-115.96%-45.4%-12.47%-0.07%-3.58%-5.96%20.71%0.58%14.53%19.53%24.96%8.96%5.71%7.1%-19.64%-14.32%2.03%27.09%11.58%19.99%43.62%51.58%52.16%104.76%93.93%3.32%-28.79%-
Total Current Liabilities40.6M52.03M62.77M72.16M57.51M33.2M44.94M24.34M18.63M18.11M18.36M7.08M7.42M8.09M9M9.39M8.96M7.09M6.99M6.42M7.35M4.98M3.9M4.49M3.36M2.79M3.7M2.5M
Accounts Payable12.3M20.91M23.56M37.02M25.21M27.5M39.55M19.66M16.27M15.27M15.22M5M5.15M5.77M6.45M6.62M6.45M4.78M4.82M4.36M5.86M3.05M2.72M3.27M2.57M2.72M1.54M1.28M
Days Payables Outstanding51.4555.2254.4968.8149.5150.6765.8335.3731.5831.6832.7111.5312.2813.5215.6315.2815.9511.9113.1113.9421.913.3915.3721.429.7752.6488.451.66
Short-Term Debt414K493K461K459K000000000000000000068.44K68.44K68.44K1.91M1.03M
Deferred Revenue (Current)3.15M689K2.08M2.6M0000000000000000000722.35K0000
Other Current Liabilities27.26M28.04M36.66M30.54M30.74M4.56M1.83M1.64M613K431K1.06M315K409K1.57M1.48M1.7M1.53M368K-650999.84K802.51K491.19K422.44K170.75K0250.05K195.05K
Current Ratio0.68x0.84x1.26x1.30x2.27x4.55x3.59x5.30x6.79x5.81x4.46x9.55x10.84x9.17x7.80x9.33x10.00x12.20x8.81x7.04x7.88x8.02x6.63x3.53x1.90x1.25x0.33x1.16x
Quick Ratio0.47x0.58x1.00x0.90x1.94x3.57x2.82x4.57x5.64x4.52x3.35x5.93x7.46x4.75x4.29x6.54x7.19x8.10x4.98x4.25x5.69x5.01x3.76x1.04x0.63x0.42x0.16x0.46x
Cash Conversion Cycle-12.84-15.39-13.29-11.37-9.6711.68-5.431.7513.1619.7813.4150.1150.5472.9563.2147.6649.3163.7664.5746.3941.2955.4453.7556.123.99-4.76-46.2823.61
Total Non-Current Liabilities175K217K798K995K2.53M936K1.28M970K1.12M996K1.09M5M5.15M65K168K492K321K225K4.82M4.36M5.86M3.05M2.72M3.34M68.44K278.1K49.45K2.19M
Long-Term Debt00535K00000000000000000000068.44K278.1K01.81M
Capital Lease Obligations500K42K0995K995K00000000000000000000049.45K0
Deferred Tax Liabilities876K175K263K02.53M936K1.28M970K1.12M996K1.09M5K065K168K492K321K225K0000000000
Other Non-Current Liabilities0000-995K0000000000000000000000383.4K
Total Liabilities40.77M52.25M63.57M73.15M60.04M34.13M46.22M25.31M19.75M19.11M19.44M7.08M7.42M8.16M9.16M9.88M9.28M7.31M6.99M6.42M7.35M4.98M3.9M4.49M3.43M3.07M3.75M4.7M
Total Debt414K535K996K1.45M995K00000000000000000068.44K136.88K346.54K1.96M2.83M
Net Debt-12.66M-20.88M-53.72M-53.84M-103.09M-111.08M-118.72M-103.76M-100.53M-77.94M-58.73M-37.64M-35.61M-18.3M-18.16M-46.8M-49.66M-53.14M-30.13M-20.27M-316.47K-23.22M-12.68M-3.21M-847.28K-390.74K1.55M2.52M
Debt / Equity0.02x0.02x0.01x0.02x0.01x------------------0.00x0.02x0.22x2.58x1.74x
Debt / EBITDA-0.02x-0.18x15.47x0.10x------------------0.01x0.04x0.35x--
Net Debt / EBITDA0.59x--9.75x-572.79x-10.21x-3.90x-3.60x-3.12x-2.08x-1.44x-1.51x-1.14x-1.26x-0.63x-0.65x-1.71x-1.44x-1.27x-0.86x-0.71x-0.01x-1.24x-0.97x-0.33x-0.22x-0.40x--
Interest Coverage-70.01x-----25.23x-----------------1339.10x--14.07x-110.48x
Total Equity22.99M28.94M85.13M96.73M109.97M142.19M141.28M130.01M134.68M115.73M93.37M83.19M75.44M70.22M64.01M81.18M97M96.86M74.97M67.03M53.86M37.64M24.22M13.99M5.59M1.58M757.29K1.63M
Equity Growth %-187.28%-66.01%-11.99%-12.04%-22.66%0.64%8.67%-3.47%16.37%23.95%12.23%10.29%7.43%9.69%-21.15%-16.31%0.15%29.2%11.84%24.45%43.1%55.43%73.05%150.23%253.36%109%-53.56%-
Book Value per Share1.061.384.134.745.416.987.026.486.575.664.584.113.753.503.193.924.284.263.192.762.221.551.020.590.270.080.080.26
Total Shareholders' Equity22.99M28.94M85.13M96.73M109.97M142.19M141.28M130.01M134.68M115.73M93.37M83.19M75.44M70.22M64.01M81.18M97M96.86M74.97M67.03M53.86M37.64M24.22M13.99M5.59M1.58M757.29K1.63M
Common Stock22K21K21K21K21K21K20K20K21K21K21K20K20K20K20K20K22K23K22.69K23.73K24.31K23.97K23.46K21.86K18.46K16.36K16.36K6.37K
Retained Earnings3.12M9.26M66.54M71.56M91.66M130.5M134.14M126.18M122.17M106.32M86.53M78.3M72.34M68.65M63.99M81.11M97.11M94.31M75.16M58.64M38.62M24.17M12.11M4.1M-1.71M-4.97M-5.8M-2.97M
Treasury Stock0000000000000000000-34.28K00000000
Accumulated OCI000000000-6.17M-4.05M-8.4M-54K-37K-2K44K-141K-108K-219.75K-2.92M-2.33M-1.8M-1.96M-1.39M-840K-831.86K-771.04K0
Minority Interest0000000000000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Liquidity and capital erosion

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q4)

Rapid Asset Base Contraction Observed

As reported in recent financial filings, PETS has seen its total assets decline from $175.1M in 2024Q4 to $81.2M in 2026Q4, a trend that underscores the rapid erosion of the company's balance sheet strength as it struggles to maintain its competitive position in the pet pharmacy market.

The consistent reduction in total assets suggests that the company is liquidating or consuming its resource base to fund ongoing operations rather than reinvesting for growth. This trajectory indicates a business model in retreat, where the shrinking asset base may eventually limit the firm's ability to support its core pharmacy fulfillment infrastructure.

Liquidity Buffer Facing Severe Pressure

Based on the company's reported figures, the current ratio has deteriorated from 1.30 in 2024Q4 to 0.84 in 2026Q4, signaling that the firm's ability to cover short-term obligations is increasingly compromised as cash reserves dwindle to $21.4M against a backdrop of persistent operational losses.

The decline in the current ratio below parity suggests that the company is becoming reliant on external liquidity or further asset liquidation to meet its immediate liabilities. Investors should monitor this trend closely, as the current cash runway appears insufficient to support the business if the current burn rate persists without a structural turnaround.

Retained Earnings Erosion Signals Distress

According to the provided balance sheet data, retained earnings have plummeted from $71.6M in 2024Q4 to $9.3M in 2026Q4, reflecting a significant destruction of shareholder equity as the company continues to absorb substantial net losses while failing to generate sustainable internal capital.

The rapid depletion of retained earnings indicates that the company's historical profitability has been entirely reversed, forcing a reliance on existing equity to absorb operating deficits. This trend warrants further investigation into whether the current capital structure can remain viable without significant dilution or a fundamental shift in the cost-to-revenue ratio.

Goodwill Impairment Risks Loom Large

As indicated by the financial statements, the company's goodwill balance dropped from $26.7M in 2025Q4 to $10.8M in 2026Q4, suggesting that management has begun to recognize the diminished value of past acquisitions in the face of the current operational downturn.

The significant write-down of goodwill implies that previous strategic investments have failed to deliver the expected synergies or market share gains. This development suggests that the remaining intangible assets may still be subject to further impairment if the core pharmacy business continues to lose active customers to larger, more integrated e-commerce competitors.

PETS — Frequently Asked Questions

Quick answers to the most common questions about buying PETS stock.

What are the total assets of PetMed Express, Inc. (PETS)?

As of 2026, PetMed Express, Inc. (PETS) had total assets of $81.2M including $43.6M in current assets.

How much debt does PetMed Express, Inc. (PETS) have?

PetMed Express, Inc. (PETS) carries total debt of $0.5M, offset by $21.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of PetMed Express, Inc.?

PetMed Express, Inc. (PETS) has total shareholders' equity (book value) of $28.9M ($1.38 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is PetMed Express, Inc.'s current ratio and liquidity?

PetMed Express, Inc. (PETS) reported a current ratio of 0.84x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.